Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations

NCT06452277 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT06452277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06452277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-line Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With HER2-activating Mutations
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Recruiting
Start date
August 28, 2024
Completion date
June 27, 2029
Enrollment
555 (estimated)
Sites
279

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer, her2 mutation